Cutler Group’s Stoke Therapeutics STOK Stock Holding History

Cutler Group’s Portfolio STOK Stock Details STOK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	$1K	Buy	+2,700	New	+$16.4K	﹤0.01%	2114
2020 Q4	–	Sell	-1,500	Closed	-$7K	–	5462
2020 Q3	$7K	Buy	+1,500	New	+$42.8K	﹤0.01%	3273

Other funds holding STOK

Skorpios Trust Limassol, Cyprus $53.2M AUM 90.96% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Cutler Group's STOK Position: Q1 2024 in Review

Cutler Group sold out of Stoke Therapeutics (STOK) in Q1 2024, closing a stake of 600 shares — an estimated $3.63K sold.

Cutler Group first reported a position in STOK in Q3 2023 and held it in 2 quarters. The position peaked at $3K in Q4 2023. 103 funds tracked by Wall St. Rank hold STOK as of Q1 2024.

Cutler Group reported no remaining Stoke Therapeutics position as of Q1 2024 after selling out during the quarter.
Cutler Group sold 600 Stoke Therapeutics shares in Q1 2024, an estimated $3.63K.
Cutler Group first reported a position in Stoke Therapeutics in Q3 2023 and held it in 2 quarters.
Cutler Group's Stoke Therapeutics position peaked at $3K in Q4 2023.
103 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q1 2024.

Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.